Development strategy

Altevax has started the clinical development of a vaccine against brain tumours (glioblastoma), a particularly difficult cancer to treat today (3% survival rate 5 years after diagnosis). If successful, this vaccine will reach the market in 10 years.

In parallel, Altevax is seeking to build co-development or sub-license partnerships with pharmaceutical companies for other cancers than glioblastoma, especially with companies that own antigens that have been proven to work, but require a powerful adjuvant to be effective in humans.

Contact

Victor Vadaneaux, President
victor.vadaneaux@altevax.com
+33 9 70 40 54 00

Altevax SAS
55 Avenue Marceau - 75116 Paris
France
© Copyright Altevax 2018 - All Rights Reserved
Mentions légales : Site et contenus propriétés d'Altevax
Création et intégration : Justine Gélis / Justincreations.fr
Hébergeur OVH